Drug Combination Details
| General Information of the Combination (ID: C24324) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Sulindac Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Up-regulation | Apoptosis | ||||
| In-vivo Model | Colon carcinogenesis in five-week-old male was induced by azoxymethane. | |||||
| Experimental
Result(s) |
EGCG with sulindac synergistically suppresses ACF formation by enhancing apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett. 2002 Mar 8;177(1):49-56. | |||
